Hypertension
The risk ratios of hypertension (17 trials of 6 HIF-PHIs, containing
14,094 participants[2, 12, 16, 27-35, 37-39, 41]) were statistically
lower in the Vadadustat (RR: 0.81, 95% CI: 0.68-0.97, p=0.02,
I2=1.5%), and no remarkably increase risk in
Roxadustat, Enarodustat, Daprodustat, Desiduatat, and Molidustat
compared with ESAs (Figure 4).